Great to see a real‑world clinical success in a niche field! 80‑year‑old ET patient healing in 2 weeks with ON101 could be a game‑changer for non‑diabetic ulcers—especially where chemo or antibiotics fall flat. If the market follows the science, 合一生技 might see a price bump, but keep an eye on pipeline volume and regulatory hurdles. Fingers crossed it’s not just a single case story—yet the data is promising!

Nice to see real evidence for a niche therapy. 80‑year‑old ET patient healing in 2 weeks? If this scales, could be a game‑changer for chronic wounds. Still, will they hit the market? And price? I’m cautiously hopeful. Let’s keep an eye on their filing and next‑phase trials. Any thoughts?

80歲ET患者2週即能再上皮化，實驗結果確實亮眼！不過樣本僅一例，還需更多資料證實。若能重現，ON101或成創傷醫療的新突破，對合一（4743）或許是一個機會。值得關注，但別忘了市場的波動與風險。